Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1

Antibody‐based drugs targeting the PD‐1/PD‐L1 axis have become widely used in clinical treatments. However, challenges such as high costs and suboptimal clinical response rates have fueled growing interest in developing small‐molecule inhibitors. Recent clinical trials, both domestically and internationally, have evaluated several small‐molecule inhibitors. Notable compounds like CA‐170 and INCB086550 have shown promising properties and potential in these studies. Although no small‐molecule inhibitors targeting PD‐L1 have yet been approved for clinical use, the path to their development and clinical translation is fraught with challenges. Researchers are actively exploring innovative strategies for drug design and synthesis, while carefully assessing critical factors such as safety and efficacy. Given the essential role of the PD‐1/PD‐L1 pathway in immune evasion by tumors, this review provides a concise overview of the signaling and structure of PD‐1/PD‐L1, summarizes current progress on clinical candidate drugs targeting this pathway, discusses the challenges in translating small‐molecule inhibitors to clinical practice, and outlines future directions in drug development.

• Publication year

  2026

• Venue

  ChemMedChem

• Publication date

  2026-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/cmdc.202500972PMID 41656010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative druggability of PD-1/PD-L1 inhibitors (A56, HD10): Cross-species differences in PD-L1 exposure and efficacy.

  2025cited by this paper
• Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications

  2025cited by this paper
• Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy

  2025cited by this paper
• FH-2001 is a novel FGFR/VEGFR dual inhibitor with immune-modulating activity.

  2025cited by this paper
• An endoplasmic reticulum-targeting photodynamic AMPK agonist activates breast cancer immunotherapy through promoting immunogenic cell death and downregulation of PD-L1

  2025cited by this paper
• Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors.

  2024cited by this paper
• Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer

  2024cited by this paper
• AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1/PD-L1 Axis in the Tumor Microenvironment

  2024cited by this paper
• Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy

  2024cited by this paper
• An updated patent review on PD-1/PD-L1 antagonists (2022-present)

  2024cited by this paper
• Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy.

  2024cited by this paper
• Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges

  2024cited by this paper
• Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets.

  2024cited by this paper
• The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

  2024cited by this paper
• Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against PD-1/PD-L1.

  2024cited by this paper
• Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024).

  2024cited by this paper
• Small-molecule in cancer immunotherapy: Revolutionizing cancer treatment with transformative, game-changing breakthroughs.

  2024cited by this paper
• Demethylzeylasteral induces PD-L1 ubiquitin–proteasome degradation and promotes antitumor immunity via targeting USP22

  2024cited by this paper
• Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

  2023cited by this paper
• Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy.

  2023cited by this paper
• 134P A phase I study exploring the safety and tolerability of the small molecule PD-L1 inhibitor INCB099318 in select advanced solid tumors

  2023cited by this paper
• CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma

  2023cited by this paper
• 700P First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors

  2023cited by this paper
• Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics

  2023cited by this paper
• Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity

  2023cited by this paper
• Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors.

  2023cited by this paper
• Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis

  2023cited by this paper
• Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

  2023cited by this paper
• Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells

  2023cited by this paper
• Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment

  2023cited by this paper
• Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy.

  2023cited by this paper
• Cancer statistics, 2023

  2023cited by this paper
• Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor

  2022cited by this paper
• Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation.

  2022cited by this paper
• Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization

  2022cited by this paper
• 774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors

  2022cited by this paper
• Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.

  2022cited by this paper
• Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments

  2022cited by this paper
• Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells

  2022cited by this paper
• Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors

  2022cited by this paper
• YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer

  2022influential reference
• Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.

  2021cited by this paper
• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

  2021cited by this paper
• The foundations of immune checkpoint blockade and the ipilimumab approval decennial

  2021cited by this paper
• Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

  2021cited by this paper
• 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

  2021cited by this paper
• The PD‐1/PD‐L1 binding inhibitor BMS‐202 suppresses the synthesis and secretion of gonadotropins and enhances apoptosis via p38 MAPK signaling pathway

  2021cited by this paper
• Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies

  2021cited by this paper
• PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

  2021cited by this paper
• Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug

  2021cited by this paper
• Advances in covalent kinase inhibitors.

  2020cited by this paper
• Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity

  2020cited by this paper
• Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo

  2020cited by this paper
• IRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival

  2020cited by this paper
• Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.

  2020cited by this paper
• Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.

  2020cited by this paper
• A decade of immune-checkpoint inhibitors in cancer therapy

  2020cited by this paper
• Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export

  2020cited by this paper
• Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

  2020cited by this paper
• 419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial

  2020cited by this paper
• Human and mouse PD-L1: similar molecular structure, but different druggability profiles

  2020cited by this paper
• PD‐1/PD‐L1

  2019cited by this paper
• Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

  2019cited by this paper
• Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1

  2019influential reference
• CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?

  2019cited by this paper
• Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

  2019cited by this paper
• P2.06-07 Phase 1 Study of CA-170: First-in-Class Small Molecule Targeting VISTA/PD-L1 in Patients with Malignant Pleural Mesothelioma

  2019cited by this paper
• Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

  2018cited by this paper
• Cancer immunotherapy using checkpoint blockade

  2018cited by this paper
• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma

  2018cited by this paper
• A small molecule human PD-1/PD-L1 inhibitor promotes T cell immune activation and reduces tumor growth in a preclinical model

  2018cited by this paper
• Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.

  2018cited by this paper
• Recent advances in small molecule based cancer immunotherapy.

  2018cited by this paper
• A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

  2018cited by this paper
• Humanized Mice for the Study of Immuno-Oncology.

  2018cited by this paper
• Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis

  2018cited by this paper
• Nivolumab and Ipilimumab in Advanced Melanoma.

  2017cited by this paper
• Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

  2017cited by this paper
• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

  2017cited by this paper
• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

  2017cited by this paper
• 1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

  2017influential reference
• In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

  2017cited by this paper
• Inhibition of PLD1 activity causes ER stress via regulation of COPII vesicle formation.

  2017cited by this paper
• Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

  2016influential reference
• Ipilimumab plus nivolumab for advanced melanoma.

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators

  2016cited by this paper
• Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

  2016cited by this paper
• Engineering Escherichia coli for high-yield geraniol production with biotransformation of geranyl acetate to geraniol under fed-batch culture

  2016cited by this paper
• Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Big opportunities for small molecules in immuno-oncology

  2015cited by this paper
• Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

  2015cited by this paper
• Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

  2015cited by this paper
• Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.

  2015cited by this paper
• Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper

• No citing papers are available for this paper.